BBOX1 and hepatocellular carcinoma: To further validate whether BBOX1-AS1 promotes HCC progression and sorafenib resistance through the miR-361-3p/PHF8 axis, miR-361-3p inhibitor and siPHF8 were used to implement rescue experiments.